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use#LAAAlthough whether to perform tight glycemic control 
(TGC) in the adult intensive care unit (ICU) continues to 
be debated among intensivists and endocrinologists 
world  wide, how to report and assess TGC took a con-
structive step forward with the publication of the 
consensus recommendations in this issue of Critical Care
[1]. Th  e authors, some of whom are the principal 
investigators from many of the major adult TGC trials in 
the ﬁ   eld, present a compelling case for uniformity in 
assessment and reporting of future trials.
Th  e group discussed and made recommendations in 
ﬁ  ve areas: (a) measurement of intermittent blood glucose 
(BG) and characterization of those measurements, (b) per-
formance standards for BG measurement devices, (c) use 
of continuous glucose monitoring (CGM), (d) assessment 
of CGM, and (e) performance of CGM. Although they 
cited much of the relevant published literature over the 
last several years, their task was daunting, particularly 
with new and improved BG measurement technology 
just recently brought to the inpatient setting [2]. Th  e 
authors ultimately produced consensus recommen  da-
tions, which are excellent ﬁ  rst steps toward the laudable 
goal of uniform assessment and reporting.
In considering adoption of new standards, one has to 
take into account the quality and quantity of evidence 
that supports them as well as the structure of the formal 
analysis of the data. Finfer and colleagues put forth many 
resolutions to open questions. If adopted by clinical 
researchers, these standards would allow the signal to be 
noticed above the noise. However, some of the ‘noise’ 
that exists in the TGC literature represents reasonable 
variability in experimental approaches to performing and 
measuring TGC as well as in real-world implementation. 
For example, the authors acknowledge that protocols that 
increase BG sampling frequency as BG drops below a 
certain range will have a lower BG mean. However, the 
meeting consensus stipulates that the central tendency be 
reported as a median of patients’ individual means, which 
does not mitigate the acknowledged bias.
When stipulating methods of measuring BG at the 
bedside in the ICU, the authors review performance of 
hospital meters from the prior generation of technology 
and rightly conclude that the meters are inadequate for 
ICU monitoring. But with a new generation of hospital 
BG meters on the market, new ICU evaluations are surely 
warranted [2]. Similarly, the cited International Standards 
Organization (ISO) and Clinical Laboratory and 
Standards Institute (CLSI) rules for BG meters are 
inappropriately generous for ICU use [3,4]; however, new 
rules have been developed by both organizations and are 
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Clinical trials over time have used a variety of 
approaches for both measuring tight glycemic 
control and reporting results. The review by Finfer 
and colleagues in this issue of Critical Care is a step 
toward consensus within the research community 
to standardize the way blood glucose is measured 
and reported in clinical trials. The authors propose 
using specifi  c measures of central tendency and 
dispersion for reporting glucose, advocate the use 
of blood gas analyzers and elimination of point-of-
care glucose monitors in the intensive care unit, and 
comment on performance of continuous glucose 
monitors. As we await the release of updated rules 
from the International Standards Organization and 
process the new rules from the Clinical Laboratory and 
Standards Institute to regulate glucose monitoring, 
these recommendations should trigger many 
more conversations within the fi  eld as we strive 
for uniformity. However, we need to be cautious in 
prematurely proposing and adopting standards of care 
that fail to account for newer technology and data in 
this rapidly growing area of research.
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© 2013 BioMed Central Ltdcurrently being rolled out [5,6]. Although blood gas 
analyzers are widely accepted to have outstanding preci-
sion and accuracy, they are not present in every ICU. 
Stipulation in a consensus document that glucose meters 
are unacceptable on the basis of prior generations of 
devices might discourage investigators from conducting 
clinical trials. In fact, the largest adult and pediatric trials 
published to date used this prior generation of devices 
with relatively low rates of severe hypoglycemia (7% and 
3%), although the pediatric trial also used a computerized 
algorithm augmented with CGM [7,8]. Th   e authors make 
similarly strong statements about the use of CGM in 
TGC, concluding that there are insuﬃ   cient data about 
perfor  mance in the ICU.
Finfer and colleagues provide a ﬁ   rst attempt at 
addressing the major issues in the ﬁ  eld of conducting 
TGC in a clinical trial. Th  e authors take a deﬁ  nitive 
position on a host of challenges facing TGC investigators, 
allowing the ﬁ  eld to move forward. Th   e phrase ‘the devil 
is in the details’ was not coined to describe clinical 
research, but those of us engaged in its conception and 
design know that it may as well have been. In trying to 
pin down many of those details, the authors are to be 
congratulated. However, it behooves all of us in the ﬁ  eld 
to continue to advance and reﬁ  ne the conversation and to 
update our conclusions with the most recently available 
devices and data so that, ultimately, in both adult and 
pediatric critical care, we can discern which populations 
derive what beneﬁ   t when a well-deﬁ   ned therapy is 
applied to their care.
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